Strongest US Cough/Cold Season In 10 Years Likely

Sales Growth For US OTC Firms May Not Offset Inflation, Exchange Headwinds, Though

Increasing numbers cough/cold drug prescriptions combined with consumers’ waning interest in flu vaccines point to 2022-2023 season rivaling decade-high levels from 2017-18 and to retailers boosting inventories through year-end, Raymond James analysts say.

• Source: Shutterstock

The US consumer health product sector’s first results from the latest quarter could indicate the start of the strongest period in a decade for OTC cough/cold product sales, analysts at Raymond James suggest.

Increasing numbers for sales of Rx cough/cold drugs combined with an apparent waning interest by consumers in receiving flu vaccines...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Marketing & Advertising

More from Business